First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids ... Updated: 8:28 AM UTC Jun 23, 2023 Editorial Standards ⓘ By MATTHEW PERRONE, AP Health Writer ...

The treatment from Sarepta Therapeutics was approved Thursday for children ages 4 and 5 with Duchenne muscular dystrophy, a rare muscle-wasting disease that causes early death.

First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids Share Updated: 4:28 AM EDT Jun 23, 2023 Infinite Scroll Enabled ...

The treatment from Sarepta Therapeutics was approved Thursday for children ages 4 and 5 with Duchenne muscular dystrophy, a rare muscle-wasting disease that causes early death.

The treatment from Sarepta Therapeutics was approved Thursday for children ages 4 and 5 with Duchenne muscular dystrophy, a rare muscle-wasting disease that causes early death.